Recombinant Human IL5RA /CD125 Protein
- Known as:
- Recombinant Human IL5RA /CD125 Protein
- Catalog number:
- cd125-002
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Proxinobio
- Gene target:
- Recombinant Human IL5RA /CD125 Protein
Related genes to: Recombinant Human IL5RA /CD125 Protein
- Gene:
- IL5RA NIH gene
- Name:
- interleukin 5 receptor subunit alpha
- Previous symbol:
- IL5R
- Synonyms:
- CDw125, CD125
- Chromosome:
- 3p26.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-18
- Date modifiied:
- 2016-10-11
Related products to: Recombinant Human IL5RA /CD125 Protein
Related articles to: Recombinant Human IL5RA /CD125 Protein
- Benralizumab reduces eosinophilia and improves outcomes in most, but not all, asthma patients. We evaluated whether baseline computed tomography (CT)-derived metrics assist in clinical response prognosis after 52 weeks. - Source: PubMed
Publication date: 2026/05/07
Bourdin ArnaudBeclin Marie FeliciaChanez PascalVachier IsabellePahus LaurieNogue ErikaSkinner SarahGaleazzi DavidBoulhais MyriamLahmar ZakariaVolpato MathildePissarra Joanade Micheaux Pierre LafayeBommart SebastienMolinari Nicolas - Piroplasmosis, including Theileriosis and Babesiosis, poses a threat to livestock health and productivity worldwide. However, the molecular mechanisms underlying breed-specific differences in resistance to piroplasmosis remain poorly understood. Compared to Bos taurus, Bos indicus generally exhibits greater resistance to diseases such as piroplasmosis and trypanosomiasis, as well as enhanced adaptability to hot and humid environments. Yunnan humped cattle, an indigenous B. indicus breed, are well adapted to coarse feed and harsh environments, yet the molecular basis of their disease resistance has not been systematically investigated. - Source: PubMed
Publication date: 2026/04/30
Chen YumingChen XiaonaLiu RongLi ChunqingXiao HengChen Shanyuan - Atopic dermatitis (AD) is a clinically heterogeneous immune-mediated skin disorder. The lack of reliable clinical stratification tools and predictive biomarkers for therapeutic response remains a critical unmet need to optimize treatment and advance precision dermatology. - Source: PubMed
Publication date: 2026/04/10
Morelli MartinaScaglione Giovanni LucaDattolo AnnaGalluzzo MarcoScarponi ClaudiaMoretta GaiaProvini AlessiaRusso FilomenaCocuroccia BarbaraSordi DonatellaTalamonti MarinaVillella ValeriaSelvi Fabio RomanoMercurio LauraPaganini ClaudiaMortato EdoardoBianchi LucaDe Pità OrnellaPallotta SabatinoScala EnricoAlbanesi CristinaMadonna Stefania - : Multiple myeloma (MM) is an incurable plasma cell neoplasm in which diagnosis and prognostication rely on invasive bone marrow examinations that may not capture biological heterogeneity across different disease sites. There is a clinical need for non-invasive biomarkers that can accurately predict treatment outcomes. : We performed a global proteomic profiling of bone marrow-derived extracellular vesicles (EVs) from nine MM patients and ten controls. A total of 8839 proteins were identified, of which 14 met predefined selection criteria. These candidates were quantified in serum-derived EVs using targeted proteomic analysis. Prognostic relevance of selected proteins was evaluated in newly diagnosed MM (NDMM) patients treated with daratumumab-containing frontline regimens ( = 26) and healthy individuals ( = 60). Progression-free survival (PFS) was analyzed using univariable and multivariable models. : IL5RA ( = 0.003) and BCMA ( < 0.001) were significantly elevated in serum EVs from MM patients compared with controls. Higher serum EV-IL5RA and EV-BCMA were associated with a trend toward shorter PFS. Combined assessment of these biomarkers enabled clear stratification of MM patients into three prognostic groups, including a cohort with markedly inferior outcomes, with a 20-month PFS of 0 ( = 0.001). In multivariable analysis, the combined serum EV-IL5RA and EV-BCMA signature suggests an independent prognostic potential (HR = 38.49 [95% CI, 1.51-47.79], = 0.015). : Serum EV-IL5RA and EV-BCMA are novel non-invasive biomarkers, measurable through routine blood testing, with strong potential to improve risk stratification in NDMM patients in the era of daratumumab-based frontline therapy. - Source: PubMed
Publication date: 2026/03/30
Shirouchi YukoShinchi HirokiHaga YoshimiMishima YukoMinowa SayuriTakayama TomokoTakahashi ShunjiMaruyama DaiUeda Koji - Earlier research observed the effects of plasma proteins on ischemic stroke (IS). This Mendelian randomization (MR), in vivo study additionally assesses the associations of localized populations of plasma proteins with IS to further confirm the causality and explore drug targets. - Source: PubMed
Publication date: 2026/03/17
Ren HaoxuDing YingyueWang RuonanLi JinjianYang ChenganWang XuZhao Dexi